Literature DB >> 24079817

Validation of the allergic rhinitis treatment satisfaction and preference scale.

Ralph R Turner1, Marcia A Testa, Johanna F Hayes, Maxwell Su.   

Abstract

Allergic rhinitis (AR) affects 7.8% of U.S. adults and 10-30% of the population worldwide. AR symptoms (rhinorrhea, congestion, sneezing, nasal/ocular pruritus, and postnasal drainage) significantly impact sleep and reduce cognitive and emotional functioning affecting work and school productivity. Although effective, intranasal corticoid (INS) steroid delivery systems are often associated with adverse sensory attributes, affecting patient adherence and reducing efficacy. Patient satisfaction with treatment characteristics predicts adherence levels that can better inform treatment decisions. This study was designed to evaluate psychometric evidence for the self-administered Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) scale as a patient-reported outcomes measure for use in clinical research. Analytic methods included qualitative analysis of patient focus groups and psychometric analysis of scale data collected from 185 AR subjects enrolled in a randomized, 2-week, crossover, comparative U.S. clinical trial. Qualitative analysis conceptually supported nine treatment satisfaction subscales. Reliability by Cronbach alpha met accepted standards. Evidence was found for construct validity using structural equation modeling, criterion validity from correlation patterns between treatment satisfaction and health-related quality of life scales, and discriminant validity analysis based on AR symptom-defined groups. Responsiveness was shown by significant change in treatment satisfaction subscales among AR symptom change groups. Scores on treatment preference items discriminated between the aqueous and aerosol INS formulations. The ARTSP scale is a conceptually sound, reliable, valid, and responsive measure of patient evaluations of alternative therapies, providing detailed information about treatment characteristics that are likely to influence adherence levels and subsequent AR clinical control.

Entities:  

Mesh:

Year:  2013        PMID: 24079817     DOI: 10.2500/aap.2013.34.3715

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  4 in total

1.  Does allergic rhinitis affect communication skills in young adults?

Authors:  Can Cemal Cingi; Öner Sakallıoğlu; Nuray Bayar Muluk; Cemal Cingi
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-03       Impact factor: 2.503

2.  Perspectives on chronic urticaria/angioedema and its treatment.

Authors:  Joseph A Bellanti; Russell A Settiane
Journal:  Allergy Asthma Proc       Date:  2014 Jan-Feb       Impact factor: 2.587

3.  Facial Candling for the Treatment of Allergic Rhinitis in Young Adults: A Qualitative Study.

Authors:  Nor Faizatul F Ismail; Chin Fen Neoh; Qi Ying Lean; Amir H Abdullah; Siong Meng Lim; Kalavathy Ramasamy; Rahul P Patel; Long Chiau Ming; Yee Chang Soh
Journal:  J Pharm Bioallied Sci       Date:  2018 Oct-Dec

4.  Treatment satisfaction and quality of life in patients treated with fingolimod.

Authors:  Claude Mékiès; Olivier Heinzlef; Béatrice Jenny; Anne-Laure Ramelli; Pierre Clavelou
Journal:  Patient Prefer Adherence       Date:  2018-05-22       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.